KIR3DL1 and plasma cell myeloma: Moreover, a first clinical trial showed that isolated KIR–ligand-mismatched NK cells can be safely administrated to myeloma patients though the contribution of NK cells, in addition to the conditioning regime, could not be established in this trial [16].